Key result
High-on-clopidogrel platelet reactivity is suggested to be one of the main causes of major adverse cardiovascular events in patients with acute coronary syndrome despite adequate antiaggregant treatment.
Answers are grounded in this paper and cite their sources.
High-on-clopidogrel platelet reactivity is suggested as a main cause of thrombotic events despite adequate antiaggregant treatment in ACS and PCI patients.
Antiaggregant therapy with aspirin and clopidogrel has an important role in treatment of patients with acute coronary syndrome (ACS) to reduce the risk of major adverse cardiovascular events (MACE; myocardial infarction, cardiovascular death, stent thrombosis and stroke) [1]. Clopidogrel has a substantial benefit in high-risk patients undergoing percutaneous coronary intervention (PCI) and stent implantation. Despite adequate antiaggregant treatment, MACE occur in these patients. Patients who develop MACE have a high-on-clopidogrel platelet reactivity (HPR), suggesting that inadequate responsiveness to clopidogrel is one of the main causes of thrombotic events.
No takes yet. Share an insight, caveat, or question.
Giusti et al. (2012) conducted a review in Acute coronary syndrome (ACS). Clopidogrel was evaluated. High-on-clopidogrel platelet reactivity is suggested to be one of the main causes of major adverse cardiovascular events in patients with acute coronary syndrome despite adequate antiaggregant treatment.
Synapse has enriched 10 related papers. Consider them for comparative context: